AstraZeneca Shows That With Immune Cancer Drugs, No One Knows What's Next

May 15, 2017 · forbes.com

960x0

Shares in AstraZeneca are up 9% to $33.82 after the London-based drug giant announced that its cancer drug Imfinzi worked in a clinical trial to slow the progression of lung tumors in patients whose cancer was not treatable with surgery, capping off a week that's driven home a clear message about a class of cancer drugs Wall Street analysts think could be generating $30 billion in annual sales over the next decade. The message? You puny humans have no idea what is going to happen next.

These medicines work by blocking a signal that cancer cells use to tell white blood cells not to kill them. The two leaders in the class--Opdivo from Bristol-Myers Squibb and Keytruda from Merck--block PD-1, the signal sent out by the white blood cell. Imfinzi and Tecentriq, from Roche, block PD-L1. The expectation has been that these drugs are basically the same, yet Keytruda succeeded against metastatic non-small cell lung cancer while Opdivo failed, and on Wednesday Tecentriq failed in bladder cancer, while Keytruda extended survival.

In a note to investors this morning, Timothy Anderson of Sanford C. Bernstein lays out why today's news is important to AstraZeneca. His back-of-the-envelope calculation shows that this market could be worth $1.7 billion or more for Astra, with no competitors in site for years. What's more, this figure is not included in Wall Street's $30 billion forecasts. It means that there could be uses for these drugs that nobody is considering in their sales numbers. (The flip side of those sales numbers: these drugs all cost in the neighborhood of $150,000 a year.)

Read Complete Article

RT @emergelab: London-based female founders join Silicon Valley trade mission.Via @techdotlondon https://t.co/r82LYnLh7v

London Living Rent will give Londoners on average incomes the chance to save for a deposit. Hear Nabiel’s story ↓… https://t.co/soLhafGz3A

"It's easy to foresee a platform whereby we can see everything going on in our house from anywhere" #SmartHome #LTW https://t.co/PE5HQD4arg

Our thoughts are with all those in Manchester impacted. Wishes to you and your families.

IBM goes back to the office, after years of working from home https://t.co/JzcITIWgKs #WFH #WorkingFromHome #Work… https://t.co/lJwLK8vFEO

Tech.London Weekly

×